#Australia #Kyoto #Ferronova #GastricCancer #MAGMAP

Ferronova's Innovative Advances in Cancer Treatment

Australian medical technology company Ferronova has recently revealed its preliminary findings from the MAGMAP trial, a promising study focused on the use of lymph node mapping in gastric and oesophageal cancer patients. This multi-centre trial involved a total of 62 participants, aiming to evaluate a new nanoparticle-based platform designed to aid clinicians in identifying sentinel lymph nodes—those critical nodes that drain a primary cancer.

The findings were presented by Dr. Markus Trochsler, the principal investigator, during the 22nd ISDE World Congress for Esophageal Diseases held in Kyoto, Japan. The trial gathered participation from various esteemed medical institutions, including the Royal Adelaide Hospital, Peter MacCallum Cancer Centre, and others, collectively showing the commitment of the medical community in advancing cancer treatment methods.

Key Outcomes of the MAGMAP Trial

Among the essential achievements highlighted in the trial:

• - The employed nanoparticle, referred to as FerroTrace®, was administered to all 62 patients without causing any toxic effects.
• - Out of the 24 patients considered for a less invasive surgical approach, 18 (75%) had pre-operative chemotherapy. Remarkably, sentinel nodes were successfully identified in 23 of these participants, yielding an outstanding identification rate of 96%.
• - A significant milestone was reached with no false negatives detected among the seven patients with positive nodes evaluated, leading to a 0% false negative rate and a patient level negative predictive value of 100% in sentinel node pathology.
• - Additionally, for those with gastric-oesophageal junction or distal oesophageal cancers, the direction of FerroTrace drainage consistently matched that of the positive nodes, indicating the method's reliability.

Dr. Trochsler expressed optimism regarding these results. He noted that the MAGMAP trial represents a groundbreaking attempt to adapt technologies successful in breast cancer and melanoma for patients with gastric and oesophageal cancers. Previous efforts to transfer similar technologies have not yielded results, primarily due to the need for pre-surgical chemotherapy or radiotherapy, complicating the application.

“This study is the first of its kind where a marker has been injected prior to chemotherapy or radiotherapy before surgery, and it has demonstrated the ability to persist and remain detectable at the time of surgical intervention. The preliminary findings are exceptionally encouraging,” Dr. Trochsler stated.

He further emphasized the hope that these promising results might lay the groundwork for minimising surgical interventions for selected patients, ultimately leading to individualized treatment strategies that might enhance recovery and survival rates.

The Human Side of Research

Among the voices advocating for improved cancer treatment experiences is Mr. Geoff Parnell, a GI cancer survivor and the Chair of GI Cancer Trials (Australia). Mr. Parnell highlighted the challenges of patient experiences with gastric and oesophageal cancers, advocating for innovative approaches that maintain a positive quality of life. He shared his own journey of being diagnosed with cancer early and the arduous recovery that followed. His perspective adds a vital human element to the importance of ongoing research like Ferronova's MAGMAP trial.

A Vision for the Future

CEO Stewart Bartlett and the clinical team are eager to utilise the findings from the MAGMAP trial as a springboard for further exploration into the future of cancer treatment, hoping to open new avenues for doctors to personalize their approaches for gastric and oesophageal cancer patients. The upcoming phase of research will involve a larger cohort, aiming to validate these preliminary results.

Ferronova's dedication to enhancing treatment options for complex cancers aligns with its mission to improve early-stage cancer interventions, ultimately aiming to raise survival rates.

For more information about Ferronova and its endeavors in the medical technology field, visit Ferronova's official site. The company's presence at the Kyoto conference until September 18th offers further opportunities for dialogue about its innovations in cancer treatment.